Latest News
Jun 18, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines...

Jun 13, 2018

On the afternoon of June 13, 2018, we received an update from the U.S. Food & Drug Administration (“FDA”) concerning our pending approval for Generic Advair Diskus® that FDA has identified...

Jun 11, 2018

Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to increasing...

Jun 4, 2018

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila™ (pegfilgrastim-jmbd), a...

Jun 1, 2018

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected